IP Library Granted Patent US 10,960,066
Granted Patent B2
US 10,960,066 · App. 16/542,497 · Granted Mar 30, 2021

Patent

Inventors: Jing-Ren Zhang (Beijing, CN); Yang Wang (Beijing, CN); Zhensong Wen (Beijing, CN)
Assignee: TSINGHUA UNIVERSITY
A61K39/092A61P11/00A61P31/04A61P37/04C07K16/1275G01N33/56944A61K2039/54G01N2333/3156G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,960,066
App. No.
16/542,497
Granted
Mar 30, 2021
Kind
B2
Abstract

Provided is a method of treating or preventing pneumococcal disease. Also provided is a method of diagnosing pneumococcal disease.

Claims (11)

1. A method of treating a disease caused by Streptococcus pneumoniae , comprising: administering a therapeutically effective amount of a Streptococcus pneumonia putative segregation and condensation protein B (ScpB) or a formulation comprising the ScpB protein to a subject in need thereof.

2. The method according to claim 1 , wherein the disease caused by the Streptococcus pneumoniae comprises pneumonia, meningitis, or sepsis.

3. The method according to claim 1 , comprising:

administering the ScpB protein from Streptococcus pneumoniae in combination with an a capsular polysaccharide protein.

4. The method according to claim 1 , wherein the ScpB protein from Streptococcus pneumoniae is administered to the subject subcutaneously.

5. The method according to claim 1 . wherein the ScpB protein from Streptococcus pneumoniae is administered to the subject at least one time.

6. The method according to claim 5 , wherein the ScpB protein from Streptococcus pneumoniae is administered to the subject three times.

7. The method according to claim 6 , wherein the ScpB protein from Streptococcus pneumoniae is administered to the subject three times at an interval of 14 days.

8. The method according to claim 1 , wherein the subject is a mammal selected from a human, a mouse, a dog, a monkey, a sheep, a pig, a rabbit, and a camel.

9. The method according to claim 1 , wherein the formulation further comprises a pharmaceutically acceptable adjuvant.

10. The method of claim 1 , wherein the disease caused by the Streptococcus pneumoniae is sepsis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2019
From: ZHANG, JING-REN; WANG, YANG; WEN, ZHENSONG
To: TSINGHUA UNIVERSITY
Reel/Frame 050084/0452 →
Priority Claims (1)
CN 201710084202.2 · Feb 16, 2017 · national
Continuity (2)
Continuation PCTCN2017114577 · Dec 5, 2017
Related Publication 20190365880A1 · Dec 5, 2019
Cited By (1)
US 12,251,438